|View printer-friendly version|
|Results from First Human Clinical Study Demonstrate ChromaDex's NIAGEN(R) Nicotinamide Riboside Effectively Increases the Co-enzyme NAD+ and is Safe|
- Clinical Data Presented Today at the
The oral presentation and poster presented data which indicate that single doses of NIAGEN® NR can elevate the co-enzyme NAD+ in the blood by as much as 2.7-fold. In the first-in-humans clinical trial which involved dosing twelve healthy adult subjects, the group showed that blood cell NAD+ increased with single 100 mg, 300 mg and 1 gram doses of NIAGEN® NR. Average maximal increases in blood NAD+ were approximately 30% at the 100 mg dose and approximately 50% at the higher doses. Increases in blood NAD+ tended to be sustained for longer times at higher doses.
These observations validate NIAGEN® as an effective agent at elevating blood cell NAD+ metabolism in healthy human beings and are expected to support additional clinical studies that will further characterize the pharmacokinetics of NIAGEN® and associations between elevated or depressed NAD+ metabolism with other metabolic markers, diseases and conditions.
Dr. Brenner commented, "The results of this study constitute a significant milestone in the translation of NR technologies as it is the first time an increase in NAD+ in humans has been demonstrated through NR supplementation. Importantly, this initial single dose study showed an increase of NAD+ across all three doses of NR. It was, in fact, somewhat surprising that a molecule as tightly regulated and abundant as NAD+ could be elevated by single doses of NR."
Nobel Laureate Dr.
NAD+ is a critically important cellular cofactor that is required for fuel utilization and function of every cell in the human body. When fuel is oxidized, NAD+ is converted to NADH for cellular energy production. The related compound NADP is converted to NADPH for synthesis of lipids and detoxification of reactive oxygen species. In 2004, then at
In addition to functioning as a cofactor, NAD+ is required for the function of sirtuins, a family of enzymes that control gene expression, metabolism and mitochondrial functions, particularly during changing nutritional conditions. Sirtuins are key target enzymes in healthy aging, such that the search for sirtuin activators has been a major goal of academic, biotechnology and pharmaceutical research for the last decade. In 2007, Dr. Brenner reported that NR extends yeast lifespan by elevating cellular NAD and increasing sirtuin function. More recently, NR has been shown to improve the metabolism of mice on high fat diet, protect mice from noise-induced hearing loss, and protect mice from the damaging effects of mitochondrial mutations.
In the same presentations, Dr. Brenner reported a
Maintenance of sufficient levels of NAD+ is key to cellular energy metabolism and mitochondrial function. If NAD+ levels go down or are redirected (as in cancer cells), mitochondrial function erodes, creating numerous adverse effects. For example, results of a mouse study conducted by the
Published research has shown that NR is perhaps the most effective precursor to boost the co-enzyme NAD+ in the cell. NAD+ is arguably the most important cellular co-factor for improvement of mitochondrial performance and energy. In recent years, NAD+ has also been shown to participate as an extracellular signaling molecule in cell-to-cell communication. NAD+ is essential in supporting healthy cellular metabolism, including the efficient conversion of blood glucose into energy.
As organisms age, NAD+ levels are reported to drop, which leads to a decrease in mitochondrial health; this in turn may lead to age-related health issues. Low NAD+ levels limit the activity of a group of enzymes called sirtuins, which are believed to play key roles in longevity. NAD+ levels can be depleted by many of the stresses of life. By boosting NAD+, NR can increase mitochondrial health and induce creation of new mitochondria.
About the FASEB
A main aspect of this conference will be to foster exchange of information and technology between researchers working on the biochemical, molecular, genetic and cell biological aspects of NAD+ and related molecules. Moreover, the conference will provide a unique venue for those researchers worldwide who are interested in the basic and translational aspects of NAD metabolism and signaling. For more information about the conference, visit: http://www.faseb.org/SRC-NAD/Home.aspx.
Founded in 1912, the Federation of American Societies for Experimental Biology (FASEB) was originally created by three independent scientific organizations to provide a forum in which to hold educational meetings, develop publications, and disseminate biological research results. What started as a small group of dedicated scientists has grown to be the nation's largest coalition of biomedical researchers, representing 27 scientific societies and over 125,000 researchers from around the world. FASEB is now recognized as the policy voice of biological and biomedical researchers.
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in
Statements in this press release have not been evaluated by the
FASEB has no legal, business or other mutually beneficial relationship with
CONTACT: ChromaDex Company Contact: